Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 6, 2026
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsBusiness Wire · Sep 30, 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Sep 8, 2026
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire · Sep 2, 2026
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM FilingMarketBeat · Aug 17, 2026
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisGlobeNewsWire · Aug 17, 2026Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.51 | -$0.65 | Miss |
| May 12, 2026 | -$0.60 | -$0.48 | Beat |
| Mar 3, 2026 | -$0.59 | -$0.75 | Miss |
| Nov 6, 2025 | -$0.57 | -$0.65 | Miss |
| Aug 6, 2025 | -$0.52 | -$0.50 | Beat |
| May 12, 2025 | -$0.66 | -$0.52 | Beat |